Melio
Melio is developing a rapid, comprehensive bloodborne pathogen testing platform that identifies 99% of common pathogens directly from blood without requiring blood culture. Their technology integrates proprietary assays, advanced microfluidics, and machine learning to deliver precise results within hours instead of days, enabling faster, targeted treatments especially critical for newborns in NICU. The platform is pathogen-agnostic and continuously expands its detection capabilities through AI-driven software updates, allowing identification of new and rare pathogens globally without hardware changes. Melio is still in development and not yet commercialized, focusing on disrupting traditional blood culture diagnostics with a scalable, software-driven solution.
Melio
Melio is developing a rapid, comprehensive bloodborne pathogen testing platform that identifies 99% of common pathogens directly from blood without requiring blood culture. Their technology integrates proprietary assays, advanced microfluidics, and machine learning to deliver precise results within hours instead of days, enabling faster, targeted treatments especially critical for newborns in NICU. The platform is pathogen-agnostic and continuously expands its detection capabilities through AI-driven software updates, allowing identification of new and rare pathogens globally without hardware changes. Melio is still in development and not yet commercialized, focusing on disrupting traditional blood culture diagnostics with a scalable, software-driven solution.